First-review acceptance: what must be true of your Latin American device translation file

Most device teams I talk to budget translation the way they budget printing: a line item that gets bought after the technical file is "done." Then the first observation letter arrives from a Latin American regulator, the review clock stops, and the translation vendor becomes the most expensive supplier on the program. Not because the words cost a lot, but because a stopped clock delays the launch.

I'm Julio Martinez-Clark. I co-founded Amavita Sciences™ after years of filing device dossiers across Latin America with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. This piece is the pre-submission view: what has to be true of the translated file before you hand it to a regulator, if your goal is to clear technical review without a language-driven observation. It is written for regulatory affairs directors and international commercial leads who own the registration timeline.

A reviewer at DIGEMID, DIGEMAPS, MSP, COFEPRIS, ANVISA or INVIMA does not grade your Spanish or Portuguese for style. They check whether the file describes one device, consistently, in the language and form the rule requires. When it does not, the result is an observation, a deficiency letter or a request for information. The response cycle that follows is where the real cost lives.

Uruguay's device regulation is a good illustration of how the clock behaves. Under Decreto N° 3/008, Article 11, MSP authorizes registration within a maximum of 180 days from filing. If MSP raises observations, that period is suspended automatically, and the applicant has 90 days to cure them. Miss that window and the file is archived. Other regulators run different clocks, but the pattern is the same: an observation pauses your review and hands you a deadline.

The commercial cost is not the translation correction itself. It is the weeks your distributor waits, the tender window you miss, and the launch sequence you have to redraw. That is why I treat translation as a gate on the registration plan, with entry criteria, rather than a purchase order at the end.

After enough observation letters, the failure modes start to look alike. In our experience they collapse into four conditions. If all four hold, language is very unlikely to be the reason your file stops.

1. The file reads as one device

The IFU, the primary and secondary labels, the technical file summary, the risk management file and the clinical evaluation report must use the same device name, the same component names and the same intended-use sentence. When the technical summary calls a part a "delivery catheter," the IFU calls it an "introducer" and the label calls it a "sheath," a reviewer reasonably asks whether you are describing three products.

This is the single most common problem we see in files assembled from several vendors or several rounds of edits. The fix is a controlled term list built before translation starts and applied across every document, not reconciled at the end. On our medical device translation services page we describe this as one term list across the whole dossier, so reviewers do not read two different devices.

2. Numbers, units and negations survive translation intact

The errors that cause the most damage are rarely about vocabulary. They are a decimal separator flipped, a unit converted on one page and not another, a torque value or French size that drifts between the IFU and the specification, or a "do not" that quietly becomes a "do." Each of these changes the safety meaning of the document.

Spanish- and Portuguese-language conventions for decimals and thousands differ from English, and a translator who "localizes" a specification table without a rule can create a discrepancy against the original test report. Decide the convention for the whole file up front, and check every number against source.

3. Labeling content matches each country's rule, not a regional average

Every country in the region requires labeling and IFUs in its official language, but the mandatory content differs. Peru's Decreto Supremo N° 016-2011-SA, Article 137, requires device labeling and IFUs in Spanish and allows other languages alongside, provided the information matches what is in the sanitary registration. Uruguay's Decreto 3/008, Article 15, requires Spanish labeling that includes, among other items, the product's MSP registration number and the name of the responsible Director Técnico. A neutral Spanish label that ignores those country details is not "almost right." It is a different label.

Plan one master label text, then country variants with the local mandatory fields, each traced back to its rule. Our free LATAM regulatory translation matrix cites the instrument behind each language rule for twelve regulators.

4. Each document carries the right certification tier and is still current

Not every page in a dossier needs the same treatment. Technical content such as IFUs, manuals and clinical evidence is normally delivered as certified technical translation. Legal instruments such as powers of attorney, distributor letters and corporate authorizations often need sworn or judicial translation and authentication. Peru is a useful contrast: Article 28 of Decreto Supremo N° 016-2011-SA accepts a simple Spanish translation (traducción simple) of foreign-issued documents, but those documents must be no more than two years old unless they state a different validity. The Dominican Republic's Decreto 246-06, Article 32, by contrast, calls for translation by an intérprete judicial for certificates of free sale, GMP certificates and powers.

Two errors show up here. The first is under-certifying a legal document. The second is over-certifying the whole dossier, which multiplies cost without regulatory return. A third, quieter one is currency: a perfectly translated certificate that has expired by the filing date still fails. Fix the certification tier and the validity window document by document before work starts. Our apostille vs. sworn translation guide lays out the per-country picture.

One point of honesty: Amavita Sciences™ is not a sworn or official translator. Traducción oficial and tradução juramentada are legally reserved titles held by individually licensed professionals. Where a jurisdiction requires that tier, the document is routed to a licensed translator, and we tell you which documents those are before the project starts.

Our platform page describes the six-step pipeline every file goes through. I will summarize it here in plain terms, because the steps map directly onto the four conditions above.

1. Upload. The origin-language dossier arrives. We support eight source languages, so a file authored in German, Japanese or Hebrew does not have to pass through an English intermediate.
2. Localization. Direct source-to-target translation into Latin American Spanish or Brazilian Portuguese, using the client's terminology memory so that terminology decisions are made once, not re-decided per document.
3. Medical review. Bilingual clinical review by reviewers with Latin American regulatory experience. This is where a clinician catches the sentence that is grammatically correct and clinically wrong.
4. Regulatory QA. A country-by-country check against the primary instruments for the target regulator, with findings graded in four tiers: critical, high, medium and low.
5. Export package. A bilingual side-by-side deliverable, with a signed certificate of accuracy per document and per linguist.
6. Submission ready. The file leaves in the format the target regulator expects, with no English intermediate to explain.

The certificate matters more than people think. A certificate of accuracy is a signed statement that the translation is complete and faithful to the source, identifying who did the work. A missing or mismatched certificate is a common first-cycle problem. Because ours is issued per document and per linguist, each translated file carries its own record of who translated it and that it is complete, which is what an auditor or reviewer wants to see.

Before your next Latin American device filing, run the translated dossier through these questions. If any answer is "no" or "not sure," that is where your observation letter will come from.

• Is there a single approved term list for device name, components and intended use, and does every document use it?
• Have all numeric values, units and tolerances in the IFU, labels and technical summary been checked against the source test reports?
• Has every warning, contraindication and "do not" been checked for preserved negation?
• Does each country label carry that country's mandatory fields, for example the MSP registration number and Director Técnico in Uruguay?
• Is the certification tier for each document decided and recorded, with legal instruments separated from technical content?
• Is every foreign-issued certificate inside its validity window on the planned filing date, not just today?
• Does every translated document have a signed certificate of accuracy that matches the document version you are filing?
• If the source changes after translation starts, is there a version log that shows which translated files were updated?

That last question is the one that hurts most programs. Work started from a draft is work done twice, and every source revision travels through every language. Translate from an identified, versioned source.

No translation vendor can promise approval. Approval depends on your technical evidence, your classification and the regulator's own queue. What a disciplined translation file does is remove language as a reason to stop the clock. In a region where each observation cycle hands you a cure deadline, that is worth planning for.

If you want to see how the regulators actually phrase translation-grounds observations, read our breakdown of RFI anatomy across Latin American regulators and our note on translation QC for regulatory dossiers.

The fastest way to test this is with one real file. Send us one device document and the regulator you are filing with, and we will return it with the terminology, certification and formatting that regulator expects. You can start a LATAM pilot here. If the clinical side of your program also runs in Latin America, our sister company bioaccess® runs first-in-human device studies in the region, and the same terminology base can carry from your trial file into your registration file.

Julio Martinez-Clark, co-founder, Amavita Sciences™, and CEO, bioaccess®. Operator guidance only; not legal advice. Confirm current requirements with the regulator before filing.